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Summary
Background.— Obstructive sleep apnoea syndrome (OSAS) is associated with an increased risk
of arterial hypertension (AH), coronary artery disease, atrial arrhythmias, heart failure, stroke
and death. Whether OSAS inﬂuences aortic root size has not been fully investigated. The aim
of our study was to investigate aortic root diameter and aortic stiffness in OSAS.
Methods.— Using transthoracic Doppler echocardiography, we evaluated 76 patients with OSAS
(mean age 52.7± 9.5 years, 70 men [92%]) with no overt cardiovascular disease. The follow-
ing parameters were measured ofﬂine: aortic diameter at Valsalva sinuses, aortic regurgitation
(AR) grade, left ventricular (LV) mass, LV ejection fraction (LVEF, Simpson rule), systolic pul-
monary artery pressure (sPAP). Aortic stiffness (carotid-femoral pulse wave velocity, PWV) was
measured non-invasively using SphygmoCor technology.
Abbreviations: AH, arterial hypertension; AHI, apnoea-hypopnoea index; AR, aortic regurgitation; BMI, body mass index; CPAP, con-
tinuous positive airway pressure; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction;
OSAS, obstructive sleep apnoea syndrome; PWV, pulse wave velocity; sPAP, systolic pulmonary arterial pressure.
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Results.— Mean duration of OSAS was four years and 84% of patients were being treated with
continuous positive airway pressure. AH was documented in 39 (51%) patients. The mean aortic
root diameter was 35.3± 3.8mm (26.9—44.6mm) and the prevalence of aortic root dilatation
was 3.9% (3 of 76 patients). On univariate analysis, age and sex were signiﬁcant predictors of
aortic root dilatation whereas arterial hypertension was not.
Conclusions.— The prevalence of aortic root enlargement was not increased in OSAS. Only age
and sex and not arterial hypertension, were associated with aortic dilatation.
© 2008 Published by Elsevier Masson SAS.
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Résumé
But de l’étude.— Le syndrome d’apnée obstructive du sommeil (SAOS) est associé à une aug-
mentation du risque d’hypertension artérielle, de maladie coronaire, de ﬁbrillation auriculaire,
d’insufﬁsance cardiaque, d’accident vasculaire cérébral et de décès. Une éventuelle relation
entre le syndrome d’apnées du sommeil et la dilatation aortique n’a jamais été étudiée. Le
but de cette étude était de mesurer les diamètres aortiques et la rigidité aortique chez des
patients présentant un SAOS.
Méthodes.— Une échocardiographie transthoracique a été réalisée chez 76 patients présen-
tant un SAOS (âge moyen 52.7± 9.5 years, 70 hommes [92 %]) sans antécédent cardiovasculaire
connu. Les paramètres suivants ont été mesurés off-line : diamètre aortique au niveau des
sinus de Valsalva, insufﬁsance aortique (IA), masse ventriculaire gauche, rapport h/R, fraction
d’éjection ventriculaire gauche (par la méthode de Simpson) et les pressions artérielles pul-
monaires. La rigidité aortique a été évaluée par la mesure de la vitesse de l’onde de pouls
carotido-fémorale (VOP).
Résultats.— La durée moyenne du SAOS était de quatre années et 84 % des patients étaient
traités par pression positive continue. Une hypertension artérielle (HTA) a été documentée
chez 39 patients (51 %). Le diamètre aortique moyen était de 35.3± 3.8mm (26.9—44.6mm)
et la prévalence de la dilatation aortique était de 3.9 % (3/76 patients). En analyse univariée,
l’âge et le sexe étaient des facteurs prédictifs signiﬁcatifs de dilatation aortique mais non
l’hypertension artérielle.
Conclusion.— La prévalence de la dilatation aortique n’est pas augmentée dans le syndrome
d’apnées du sommeil. Seuls l’âge et le sexe et non l’hypertension artérielle étaient associés à
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ntroduction
bstructive sleep apnoea syndrome (OSAS) is a disordered
reathing in which the upper airway closes repeatedly dur-
ng sleep. These repetitive partial or complete cessations
f airﬂow during sleep result in oxygen desaturation, sleep
ragmentation and excessive daytime sleepiness. OSAS is
ommon and affects up to 4% of middle-aged men and up
o 2% of women [1]. It is associated with vascular risk fac-
ors and increased cardiovascular morbidity and mortality
2]. Several studies have reported that OSAS is indepen-
ently associated with arterial hypertension [3], coronary
rtery disease [4,5], heart failure [6,7], stroke and death
8]. An association has also been demonstrated between
SAS and aortic stiffness [9] and an increased risk of aor-
ic dissection [10]. Whether OSAS inﬂuences aortic root size
as not yet been investigated. The aim of our study was
o investigate aortic root diameter and aortic stiffness in
atients with OSAS and to evaluate the inﬂuence of arterial
ypertension.
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tudy population
e conducted an observational cohort study in patients with
SAS who were referred consecutively for a cardiovascu-
ar evaluation by the Saint-Antoine sleep disorders centre
etween March 2005 and March 2007. The study was per-
ormed in patients included in our outpatient clinic, with
egular examinations that did not require the patient’s writ-
en consent. All information was, however, given to the
atients.
Data on patient’s demographic characteristics, sleep and
edical history, cardiovascular risk factors and medica-
ion use and habits were obtained during a consultation.
ata on risk factors included a history of hypertension
deﬁned as systolic blood pressure greater or equal to
40mmHg and/or diastolic blood pressure greater or equal
o 90mmHg and/or use of antihypertensive medication,
eing measured with a standard sphygmomanometer on
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three different occasions with the subject in the supine
position, or blood pressure greater than 125/80mmHg dur-
ing 24-hour ambulatory blood pressure monitoring [11]),
diabetes mellitus, hyperlipidaemia, and current or former
smoking with an indication of the number of pack-years and
coronary heredity. Metabolic syndrome was deﬁned accord-
ing to the National Cholesterol Education Program—Adult
Treatment Panel III (NCEP ATP-III) guidelines [12]. The
diagnosis required at least three of the following crite-
ria: fasting glycaemia greater than 6.1mmol/L (1.1 g/L),
fasting triglycerides greater than 1.7mmol/L (1.5 g/L),
high-density lipoprotein cholesterol lesser than 1mmol/L
(men) or 1.3mmol/L (women) (0.6 and 0.5 g/L), blood
pressure greater than 130/85mmHg, and waist circumfer-
ence greater than 102 cm (men) or greater than 88 cm
(women). Data regarding medications included the daily use
of beta-blockers, angiotensin converting-enzyme inhibitors
or angiotensin-receptor antagonists, diuretics, calcium-
channel blockers, oral medications or insulin for the
treatment of diabetes, and lipid-lowering medications.
Each patient’s height and weight were recorded to deter-
mine their body mass index (BMI). Patients underwent a
clinical examination, including biological samples (routine
biochemical investigation, fasting glucose, insulin, lipids
and high-sensitivity C-reactive protein), an electrocardio-
gram, a chest X-ray, ambulatory blood pressure monitoring,
Holter monitoring, and transthoracic echocardiography.
Aortic stiffness (carotid-femoral pulse wave velocity
[PWV]) was measured non-invasively using SphygmoCor®
technology.
Echocardiography
Transthoracic echocardiography was performed with a GE
Vingmed Vivid 7 dimension with a 2.5-MHz transducer
according to the recommendations of the American Soci-
ety of Echocardiography [13]. All echocardiograms were
reviewed and were excluded from the analysis if they had
inadequate two-dimensional images for the assessment of
ascending aorta dimensions. Aortic root diameter was mea-
sured according to Roman et al.’s [14] recommendations at
end-diastole, in the parasternal long-axis view at four levels:
• the annulus;
• the sinuses of Valsalva;
• the supra-aortic ridge;
• the proximal ascending aorta.
Aortic root dilatation was identiﬁed when aortic root
diameter at the sinus of Valsalva was greater than two stan-
dard deviations (SD) above the regression line with body
surface area in a previously studied reference population
[14]. Aortic regurgitation was semiquantiﬁed as mild, mod-
erate, or severe, based on other ﬂow mapping and usual
indices [15].
Left ventricular end-diastolic diameter and end-systolic
diameter were measured by M-mode echocardiography
from two-dimensional echocardiography according to the
recommendations of the American Society of Echocar-
diography [16]. The left ventricular mass index was
calculated according to Devereux et al. [17]. LVEF was
estimated visually. sPAP was calculated using the mod-
iﬁed Bernoulli equation on tricuspid regurgitation [18].
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easurements were made in three cardiac cycles, and
he average was calculated for subsequent analyses. All
oppler and echocardiographic recordings were stored on
ptical disks and were analysed off-line by a single expe-
ienced investigator blinded to the patient’s status and
reatment.
WV measurement
ortic stiffness (carotid-femoral PWV) was measured non-
nvasively using SphygmoCor® technology. All arterial
easurements were carried out during the consultation
n a central core laboratory. Measurements were per-
ormed in a controlled environment at 22± 1 ◦C after
5minutes of rest. Transcutaneous Doppler ﬂow recordings
ere carried out simultaneously at the carotid and femoral
rteries. PWV was calculated as the distance between
ecording sites measured over the surface of the body
ivided by the time travelled by the reﬂected wave. The
ime delay was averaged over 10 to 15 cardiac cycles
19].
olysomnography
ll participants underwent attended overnight polysomnog-
aphy with the use of the Cidelec® system (Angers,
rance). The recordings included a two-channel elec-
roencephalogram, electromyogram, electrocardiogram,
lectro-oculogram, body position, chest and abdominal
xcursions, naso-oral airﬂow assessed by a nasal cannula,
nd oxyhaemoglobin saturation (ﬁnger pulse oximetry). A
ingle, attended polysomnographic study conducted during
n entire night was used to establish the presence of sleep
pnoea [20].
Total cessation of airﬂow at the nose and mouth for
t least 10 seconds was classiﬁed as apnoea (as obstruc-
ive if respiratory effort was present and as central
pnoea if respiratory efforts were absent). Partial airway
losure resulting in a diminution of airﬂow by greater
han 30% for greater or equal to 10 seconds associ-
ted with oxygen desaturation greater or equal to 4%
as classiﬁed as hypopnoea [21]. Calculated polysomno-
raphic variables included the apnoea-hypopnoea index
AHI) and the percentage of total sleep time during which
he oxygen saturation was lesser than 90% (SaO2 < 90%).
leep history data included a validated measure of day-
ime sleepiness (Epworth sleepiness scale) [22]. Sleep
tudies were performed in the sleep laboratory and
ere supervised throughout by an experienced techni-
ian.
tatistical analysis
ata are expressed as means± SD or medians with interquar-
ile ranges. Pearson’s correlation analysis was used to assess
he possible relation between aortic dimensions and demo-
raphic or echocardiographic parameters, with signiﬁcance
t a critical level of ﬁve per cent or lower. A probability value
ess than 0.05 was considered statistically signiﬁcant. All
tatistical analysis was performed using STATA 9 statistical
oftware.
3 C. Meuleman et al.
R
T
7
5
3
o
p
t
d
p
p
t
d
i
e
Table 2 Characteristics of obstructive sleep apnoea
syndrome.
Characteristics
Duration of OSAS, years 4 (1, 7)
Apnoea-hypopnoea index 56.5 (33.6, 79.0)
Time spent with oxygen
desaturation lesser than 90%
12.2 (3.7, 28.0)
Epworth Sleepiness Scale score 10 (7, 16)
Treatment of OSAS 66 (87)
Treatment with CPAP, n (%) 64 (84)
Duration of CPAP, years* 1.0 (0.3, 6.0)94
esults
able 1 summarizes the baseline characteristics of the
6 patients included in the study. The mean age was
2.7± 9.6 years, 70 (92%) were men, and the mean BMI was
1.5± 5.8 kg/m2. Thirty-nine (51%) patients had evidence
f hypertension at baseline examination. Of these, 25 (64%)
atients had a history of hypertension with a mean dura-
ion of 6.4± 4.7 years and 14 (36%) were newly diagnosed
uring the cardiovascular evaluation or by ambulatory blood
ressure monitoring. A history of hypercholesterolaemia was
resent in 39 (51%) patients of whom 17 (44%) were being
reated with statins or ﬁbrates. Thirteen (17%) patients had
iabetes mellitus, two of whom were being treated with
nsulin and four with oral hypoglycaemic drugs, and the oth-
rs with diet. Metabolic syndrome was present in 37 (49%)
Table 1 Baseline characteristics of the study popula-
tion (n = 76).
Baseline characteristics
Age, years 52.7± 9.6
Male sex, n (%) 70 (92)
Current smoker, n (%) 26 (34)
Hypertension, n (%) 39 (51)
Newly-diagnosed hypertension, n (%) 14 (36)
History of hypertension, n (%) 25 (64)
Time from hypertension diagnosis,
years*
6.4 (4.7)
Antihypertensive treatment, n (%)* 23 (92)
Hypercholesterolaemia 39 (51)
Lipid-lowering treatment 17 (44)
History of diabetes mellitus, n (%) 13 (17)
Diabetes mellitus treatment, n (%) 6 (46)
Metabolic syndrome, n (%) 37 (49)
Family history of coronary artery disease,
n (%)
9 (12)
Physical measurements
BMI, kg/m2 31.5± 5.8
Waist/hip ratio 1.00± 0.06
Systolic blood pressure, mmHg 137± 16
Diastolic blood pressure, mmHg 81± 8
Pulse pressure, mmHg 56± 13
Heart rate, bpm 71± 12
Pulse wave velocity, m/s 9.8± 1.7
Blood measurements
Fasting glucose, mmol/L 5.82± 2.30
Fasting insulin, mU/L 11.81± 6.22
HOMA-IR 3.19± 2.35
Total cholesterol, g/L 1.97± 0.38
Triglycerides, g/L 1.40± 0.71
HDL-cholesterol, g/L 0.45± 0.12
LDL-cholesterol, g/L 1.27± 0.33
Creatinine, mol/L 95.45± 12.28
C-reactive protein, mg/L 5.15± 9.75
Values are mean± SD unless otherwise speciﬁed.
HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment—insulin resistance; LDL, low-density lipoprotein.
* Only available for patients with a history of hypertension.
Mandibular advancement device, n
(%)
7 (9)
Duration of mandibular
advancement device, years
0.6 (0.2, 2.0)
Values are median (interquartile range) unless otherwise speci-
ﬁed.
CPAP: continuous positive airway pressure; OSAS: obstructive
sleep apnoea syndrome.
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advancement device.
atients. None of these patients had a history of cardio-
ascular disease (myocardial infarction, heart failure, atrial
brillation, stroke, or aortic disease). No patient had a pre-
ious diagnosis of Marfan syndrome or related disease.
The median duration of OSAS was four years and 84% were
reated with continuous positive airway pressure (CPAP).
he median AHI was 56.5/h (minimum 11.8, maximum 188),
ith a median time spent with SaO2 < 90% of 12.2%. The
edian Epworth Sleepiness Scale score was 10 (minimum
, maximum 16) (Table 2).
Echocardiographic characteristics are shown in Table 3.
o patients had left ventricular dysfunction or pulmonary
rterial hypertension. The mean aortic root diameter was
5.3± 3.8mm (26.9—44.6mm). According to the deﬁni-
ion by Roman et al. [14], only three (3.9%) patients had
ortic dilatation deﬁned by aortic root diameter at the
inus of Valsalva greater than two SD above the regres-
Table 3 Two-dimensional echocardiographic character-
istics (n = 76).
Echocardiographic parameters
Aortic root diameter at Valsalva sinus, mm 35.3± 3.8
Aortic regurgitation (grade 1), n (%) 13 (17)
LVEDD, mm 52.5± 5.0
LVESD, mm 32.2± 4.9
Septal thickness, mm 10.4± 1.5
Posterior wall thickness, mm 9.1± 1.7
Left ventricular mass, g 89.9± 19.0
Fractional shortening, n (%) 38.7± 6.9
sPAP, mmHg 30.4± 5.5
Values are mean± SD unless otherwise speciﬁed.
LVEDD, left ventricular end diastolic diameter; LVESD, left
ventricular end systolic diameter; sPAP systolic pulmonary
artery pressure.
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Table 4 Baseline correlates of aortic root diameter in the study population.
Aortic root diameter tertiles ta tb
1st ( < 33.6) 2nd (33.6—36.8) 3rd ( > 36.8)
Aortic root diameter, mm 31.4 (0.99) 35.2 (0.99) 39.5 (2.11)
N 27 24 25
Demographic and anamnestic characteristics
Age, years 50.4 (9.3) 50.8 (9.3) 57.1 (7.6) 2.4* 2.3*
Male sex 23 (85) 23 (96) 24 (96) 2.5* 2.4*
Hypertension 13 (48) 10 (42) 16 (64) 0.7 0.6
Hypercholesterolaemia 16 (59) 10 (42) 13 (52) −0.3 −0.7
History of diabetes mellitus 5 (19) 4 (17) 4 (16) −0.3 −0.5
Metabolic syndrome 14 (52) 13 (54) 10 (40) −0.6 0.2
Physical measurements
Body mass index, kg/m2 31.7 (6.8) 31.6 (6.8) 31.2 (5.6) 0.3 1.4
Systolic blood pressure, mmHg 136 (20) 137 (20) 139 (15) 0.7 0.2
Diastolic blood pressure, mmHg 80 (9) 81 (9) 84 (8) 1.2 1.0
Pulse wave velocity, m/s 9.9 (1.7) 9.5 (1.7) 10.1 (1.6) 0.4 −1.2
OSAS characteristics
Apnoea-hypopnoea index 62.5 (31.9) 56.4 (31.9) 61.5 (38.3) 1.4 1.4
Time spent with oxygen desaturation < 90% 21.23 (21.1) 15.8 (21.1) 18.6 (18.8) 0.8 1.0
Epworth Sleepiness Scale score 9.8 (6.0) 12.5 (6.0) 10.3 (6.4) 0.9 0.7
Treatment with CPAP, n (%) 23 (85) 21 (88) 20 (80) 0.7 0.7
Echocardiographic characteristic
LVEDD, mm 50.4 (4.8) 54.2 (4.8) 53.1 (4.0) 2.0 1.9
Left ventricular mass, g 83.8 (19.7) 90.7 (19.7) 95.6 (18.7) 2.0 1.3
Fractional shortening, % 38.0 (6.3) 38.1 (6.3) 40.1 (7.3) 0.4 0.3
sPAP, mmHg 30.7(7.2) 30.3 (7.2) 30.2 (4.3) −0.1 −0.1
CPAP, continuous positive airway pressure; LVEDD, left ventricular end diastolic diameter; OSAS, obstructive sleep apnoea syndrome;
sPAP systolic pulmonary artery pressure.
Values are mean± SD or n (%).
*p < 0.05.
a Unadjusted.
b Age- and sex-adjusted t-statistic from regression of aortic root diameter on each characteristic.
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ssion line with body surface area. Mild aortic regurgitation
was present in 13 (17%) patients. No moderate or severe
aortic regurgitation was diagnosed. The mean PWV was
9.8± 1.7m/s.
The main results are presented according to tertile of
aortic diameter. Aortic root diameter was positively and
signiﬁcantly associated with age and male sex, and to
a lesser extent with left ventricular end-diastolic diam-
eter and left ventricular mass (although not statistically
signiﬁcant). No signiﬁcant correlation was found between
aortic root diameter and arterial hypertension, PWV or OSAS
(Table 4).
DiscussionTo our knowledge, this is the ﬁrst evaluation of aortic root
diameter in a large cohort of patients with OSAS. We found
that the prevalence of aortic root dilatation was 3.9% and
that the aortic root diameter was not increased in individu-
als with OSAS.
e
b
p
teterminants of aortic root dilatation
he relation between anthropometric variables and aor-
ic dimensions have been recognized and conﬁrmed in
chocardiographic studies of the aortic root [14,23,24].
ge-related dilation of the aortic root has been discussed
n autopsy series and in clinical studies. Whereas an age-
elated increase was evident in some studies [14,22], it was
ot in others [25]. Generally, aortic root dimensions are
maller in women than in men [14]. Height is suggested to
e the most important determinant of aortic root size com-
ared with body surface area or weight [23]. In some studies,
orrelations with systolic [23] and diastolic [26] blood pres-
ure have been reported whereas in others there were no
igniﬁcant correlations with either systolic or diastolic pres-
ure [14].Roman et al. [14] reported that two-dimensional
chocardiographic aortic root dimensions were inﬂuenced
y age and body size but not by blood pressure. The authors
roposed normograms presenting aortic diameter according
o age and body surface area in both children and adults.
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[96
asan et al. [24] showed that age, height, weight, and sex
ere the principal determinants of aortic root dimensions in
he Framingham Heart study, which included 1849 men and
152 women. Our study conﬁrmed a relation between age,
ex, and aortic dilatation but showed that arterial hyperten-
ion was not a predictor of aortic root dilatation.
ortic disease in patients with OSAS
n one study, patients with aortic dissection presented a
igh prevalence of previously undiagnosed and frequently
evere OSAS [10]. A higher mean AHI was found in these
atients compared with a control group of hypertensive
atients. Arterial hypertension, marked increase in sympa-
hetic activity, and increased transmural pressure of the
orta wall during apnoeas are suggested mechanisms that
ould explain aortic dissection in OSAS [10]. These mecha-
isms have been previously described in Marfan’s syndrome,
n which a high prevalence of OSAS was detected [27]. OSAS
reatment with nasal CPAP was associated with attenua-
ion of aortic root dilatation [28,29]. This treatment has
lso been shown to alleviate daytime sleepiness, improve
uality of life, decrease the occurrence of new cardio-
ascular events in patients with coronary artery disease
30], and may reduce cardiovascular morbidity and mortality
31—33].
WV and OSAS
WV is an indicator of arterial stiffness [34,35]. Nagahama
t al. [36] have shown that brachial-ankle PWV was sig-
iﬁcantly higher in patients with OSAS than in controls
ven when the degree of risk factors was equal or in the
bsence of risk factors. Tanriverdi et al. [37] reported that
he elastic properties of the aorta were deteriorated in
atients with OSAS, characterized by increased aortic stiff-
ess and lower distensibility. Increased aortic stiffness might
e responsible for the alteration of left ventricular systolic
nd diastolic function reported in OSAS syndrome [36]. In
ur study, mean PWV was 9.8± 1.7m/s, and no signiﬁcant
orrelation was found between aortic root diameter and
WV.
imitations
he main limitation of this study was the absence of controls
BMI and age-matched control patients). Moreover, its ret-
ospective design and the absence of follow-up do not allow
s to draw deﬁnite conclusions. To extend these preliminary
esults, it is necessary to undertake a case-control study
nd a longitudinal follow-up to evaluate the determinants
f cardiovascular events.onclusion
hese results suggest that aortic root enlargement is not
ncreased in individuals with OSAS. Aortic root dilatation in
atients with OSAS was associated with age and sex, but not
ith arterial hypertension.
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